NO741764L - - Google Patents
Info
- Publication number
- NO741764L NO741764L NO741764A NO741764A NO741764L NO 741764 L NO741764 L NO 741764L NO 741764 A NO741764 A NO 741764A NO 741764 A NO741764 A NO 741764A NO 741764 L NO741764 L NO 741764L
- Authority
- NO
- Norway
- Prior art keywords
- rifamycin
- formula
- solvent
- compound
- oxazino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims description 15
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 10
- 229940081192 rifamycins Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 229930189077 Rifamycin Natural products 0.000 description 8
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 8
- -1 crotyl Chemical group 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229940109171 rifamycin sv Drugs 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 2
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241001342522 Vampyrum spectrum Species 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- RREWVUUCVMWQOY-UHFFFAOYSA-N n-methyl-1-(2-methylpropoxy)-n-(2-methylpropoxymethyl)methanamine Chemical compound CC(C)COCN(C)COCC(C)C RREWVUUCVMWQOY-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YIHVBAAISJNGLN-UHFFFAOYSA-N N,N-bis(methoxymethyl)-1-phenylethanamine Chemical compound COCN(C(C1=CC=CC=C1)C)COC YIHVBAAISJNGLN-UHFFFAOYSA-N 0.000 description 1
- JIOKMFAJQMWJNW-UHFFFAOYSA-N N,N-bis(methoxymethyl)cyclohexanamine Chemical compound COCN(COC)C1CCCCC1 JIOKMFAJQMWJNW-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 150000005130 benzoxazines Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- CIQMOGCLHBWDNU-UHFFFAOYSA-N n,n-bis(ethoxymethyl)-1-phenylmethanamine Chemical compound CCOCN(COCC)CC1=CC=CC=C1 CIQMOGCLHBWDNU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2706673A IT1043857B (it) | 1973-07-25 | 1973-07-25 | Derivati delle rifapicime procedimento della loro sintesi e loro impiego quali intermeni per la produzione di sofamicine |
| IT1977474A IT1054154B (it) | 1974-01-24 | 1974-01-24 | Procedimento per la preparazione di ossazino rifamione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO741764L true NO741764L (ja) | 1975-02-24 |
Family
ID=26327298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO741763A NO142305C (no) | 1973-07-25 | 1974-05-15 | Fremgangsmaate for fremstilling av 3-iminometylderivater av rifamycin sv. |
| NO741764A NO741764L (ja) | 1973-07-25 | 1974-05-15 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO741763A NO142305C (no) | 1973-07-25 | 1974-05-15 | Fremgangsmaate for fremstilling av 3-iminometylderivater av rifamycin sv. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US3963705A (ja) |
| JP (2) | JPS5339440B2 (ja) |
| AR (2) | AR207762A1 (ja) |
| AT (2) | AT334530B (ja) |
| BE (2) | BE815122A (ja) |
| CA (2) | CA1024139A (ja) |
| CH (2) | CH615683A5 (ja) |
| DD (2) | DD112133A5 (ja) |
| DE (2) | DE2428387A1 (ja) |
| DK (2) | DK284874A (ja) |
| ES (2) | ES429060A1 (ja) |
| FI (2) | FI153574A (ja) |
| FR (2) | FR2257297B1 (ja) |
| GB (2) | GB1454801A (ja) |
| HU (2) | HU167983B (ja) |
| IE (2) | IE39388B1 (ja) |
| IN (2) | IN138735B (ja) |
| NL (2) | NL7409892A (ja) |
| NO (2) | NO142305C (ja) |
| PH (1) | PH13691A (ja) |
| PL (1) | PL91647B1 (ja) |
| RO (1) | RO63865A (ja) |
| SE (2) | SE393112B (ja) |
| SU (2) | SU613725A3 (ja) |
| YU (2) | YU36720B (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR207762A1 (es) * | 1973-07-25 | 1976-10-29 | Archifar Ind Chim Trentino | Procedimiento para la preparacion de 3-((4-metil-1-piperazin-1-il)-imino)-metil-rifamicina sv o rifampicina |
| GB1576886A (en) * | 1977-04-20 | 1980-10-15 | Lepetit Spa | Rifamycin derivatives |
| US4179439A (en) * | 1977-07-01 | 1979-12-18 | Intreprinderea De Antibiotice Iasi | Rifamycins and method for their preparation |
| JPS5473798A (en) * | 1977-11-15 | 1979-06-13 | Kanebo Ltd | Novel 1,3-oxazino (5,6-c) rifamycin derivative |
| JPS5473799A (en) * | 1977-11-16 | 1979-06-13 | Kanebo Ltd | Preparation of 1,3-oxazino (5,6-c) rifamycin derivative |
| GB1594134A (en) * | 1977-11-25 | 1981-07-30 | Holco Investment Inc | Rifamycins |
| JPS5484600A (en) * | 1977-12-15 | 1979-07-05 | Kanebo Ltd | Preparation of 1,3-oxazino 5,6-c rifamycin derivative |
| JPS5776597A (en) * | 1980-10-30 | 1982-05-13 | Kiyouritsu Kurieiteibu Asoshie | Electric musical instrument |
| JPS58115705U (ja) * | 1982-02-01 | 1983-08-08 | 株式会社ニコン | カメラのフアインダ光学系 |
| GB8308166D0 (en) * | 1983-03-24 | 1983-05-05 | Erba Farmitalia | Preparation of azinomethyl-rifamycins |
| GB8318072D0 (en) * | 1983-07-04 | 1983-08-03 | Lepetit Spa | Water-soluble rifampicin derivatives |
| DE69735383T2 (de) * | 1996-11-19 | 2007-02-15 | Georgetown University | Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen |
| US20090275594A1 (en) * | 2008-05-05 | 2009-11-05 | Macielag Mark J | 3-hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents |
| CN103755723B (zh) * | 2014-02-07 | 2016-04-20 | 天津大学 | 一种利福平i晶型的制备方法 |
| CN103951677B (zh) * | 2014-03-17 | 2016-04-06 | 四川省长征药业股份有限公司 | 利福喷丁的制备方法 |
| CN106632394A (zh) * | 2016-11-15 | 2017-05-10 | 南京工业大学 | 一种利用釜式反应装置与微通道反应装置串联反应制备利福平的方法 |
| CN106749326A (zh) * | 2016-11-28 | 2017-05-31 | 南京工业大学 | 一种由利福霉素s钠盐连续生产制备利福平的方法 |
| CN111848639A (zh) * | 2020-07-09 | 2020-10-30 | 华东理工大学 | 一种合成利福平的工艺方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1090115A (en) * | 1964-04-02 | 1967-11-08 | Lepetit Spa | Mannich bases of rifamycin sv |
| FR208F (ja) * | 1964-07-31 | |||
| DE1795568C3 (de) * | 1964-07-31 | 1974-07-18 | Gruppo Lepetit S.P.A., Mailand (Italien) | 3-Hydroxymethyl-rifamycin SV und Verfahren zu seiner Herstellung. Ausscheidung aus: 1595883 |
| US3542762A (en) * | 1967-06-07 | 1970-11-24 | Lepetit Spa | Process for rifamycins |
| AR207762A1 (es) * | 1973-07-25 | 1976-10-29 | Archifar Ind Chim Trentino | Procedimiento para la preparacion de 3-((4-metil-1-piperazin-1-il)-imino)-metil-rifamicina sv o rifampicina |
-
1974
- 1974-01-01 AR AR254828A patent/AR207762A1/es active
- 1974-01-01 AR AR254829A patent/AR207763A1/es active
- 1974-05-07 SE SE7406074A patent/SE393112B/xx not_active IP Right Cessation
- 1974-05-07 SE SE7406073A patent/SE407803B/xx not_active IP Right Cessation
- 1974-05-08 GB GB2025674A patent/GB1454801A/en not_active Expired
- 1974-05-08 GB GB2025774A patent/GB1454802A/en not_active Expired
- 1974-05-08 FR FR7415837A patent/FR2257297B1/fr not_active Expired
- 1974-05-09 IN IN1038/CAL/74A patent/IN138735B/en unknown
- 1974-05-09 IN IN1039/CAL/74A patent/IN139074B/en unknown
- 1974-05-14 YU YU1325/74A patent/YU36720B/xx unknown
- 1974-05-14 IE IE1034/74A patent/IE39388B1/xx unknown
- 1974-05-14 IE IE1035/74A patent/IE39389B1/xx unknown
- 1974-05-14 YU YU1324/74A patent/YU36719B/xx unknown
- 1974-05-15 NO NO741763A patent/NO142305C/no unknown
- 1974-05-15 NO NO741764A patent/NO741764L/no unknown
- 1974-05-16 BE BE144391A patent/BE815122A/xx unknown
- 1974-05-17 FI FI1535/74A patent/FI153574A/fi unknown
- 1974-05-21 RO RO7400078880A patent/RO63865A/ro unknown
- 1974-05-23 US US05/472,887 patent/US3963705A/en not_active Expired - Lifetime
- 1974-05-23 PL PL1974171342A patent/PL91647B1/pl unknown
- 1974-05-23 FI FI1575/74A patent/FI60397C/fi active
- 1974-05-23 US US472886A patent/US3925366A/en not_active Expired - Lifetime
- 1974-05-24 DK DK284874A patent/DK284874A/da unknown
- 1974-05-24 DK DK284774AA patent/DK135286B/da unknown
- 1974-05-24 CA CA200,755A patent/CA1024139A/en not_active Expired
- 1974-05-31 CA CA201,355A patent/CA1022548A/en not_active Expired
- 1974-06-10 DD DD179054A patent/DD112133A5/xx unknown
- 1974-06-12 DE DE19742428387 patent/DE2428387A1/de active Pending
- 1974-06-17 AT AT496174A patent/AT334530B/de not_active IP Right Cessation
- 1974-06-17 PH PH15952A patent/PH13691A/en unknown
- 1974-07-04 JP JP7592774A patent/JPS5339440B2/ja not_active Expired
- 1974-07-04 JP JP7592874A patent/JPS5314080B2/ja not_active Expired
- 1974-07-05 SU SU2041832A patent/SU613725A3/ru active
- 1974-07-09 SU SU742040820A patent/SU576943A3/ru active
- 1974-07-10 DE DE2433105A patent/DE2433105A1/de active Granted
- 1974-07-11 DD DD179869A patent/DD112267A5/xx unknown
- 1974-07-17 FR FR7424949A patent/FR2245631B1/fr not_active Expired
- 1974-07-18 BE BE146706A patent/BE817823A/xx not_active IP Right Cessation
- 1974-07-19 AT AT596774A patent/AT334531B/de not_active IP Right Cessation
- 1974-07-22 NL NL7409892A patent/NL7409892A/xx unknown
- 1974-07-23 NL NLAANVRAGE7409955,A patent/NL181992C/xx not_active IP Right Cessation
- 1974-07-24 ES ES429060A patent/ES429060A1/es not_active Expired
- 1974-07-24 ES ES429059A patent/ES429059A1/es not_active Expired
- 1974-07-24 HU HUAI240A patent/HU167983B/hu unknown
- 1974-07-24 CH CH1020074A patent/CH615683A5/de not_active IP Right Cessation
- 1974-07-24 CH CH1019974A patent/CH611296A5/xx not_active IP Right Cessation
- 1974-07-24 HU HUAI239A patent/HU168723B/hu unknown
-
1983
- 1983-04-11 US US06/483,683 patent/USRE31587E/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO741764L (ja) | ||
| DK162647B (da) | Fremgangsmaade til fremstilling af pyrido-imidazorifamyciner | |
| CS197271B1 (en) | Process for preparing derivatives of rifamycine | |
| AU2023229518A1 (en) | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | |
| Hata et al. | Is oxygen abstraction by nucleophilic reagents a characteristic reaction of oxaziridines? | |
| DK160829B (da) | Fremgangsmaade til fremstilling af pyrido-imidazorifamyciner | |
| Ulrich et al. | Cycloaddition reactions of isocyanates. Reaction of aryl isocyanates with N, N-dimethylformamide | |
| Salimov et al. | Synthesis and Antimicrobial Activity of 2-Bromo-7-methyl-5-oxo-5H-1, 3, 4-thiadiazolo [3, 2-a] pyrimidine | |
| KR880001284B1 (ko) | 아지노 리파마이신 화합물의 제조방법 | |
| NO165107B (no) | Fremgangsmaate for fremstilling av pyrido-imidazo-rifamycin-derivater. | |
| WO2022038166A1 (en) | Amide coupling process | |
| RU2156238C2 (ru) | Способ получения диоксоазабициклогексанов | |
| KR940009795B1 (ko) | 신규 2'-치환-4-데옥시-티아졸로[5,4-c]리파마이신 SV유도체의 제조방법 | |
| MX2013006476A (es) | Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos. | |
| KR910002841B1 (ko) | 3-아지노메틸 리파마이신의 제조방법 | |
| US3833667A (en) | Process for the preparation of 1,2-di-(o-or p-nitrophenyl)-ethanol | |
| CA1056400A (en) | Process for the preparation of 1,4-naphthodinitrile | |
| Tsukamoto et al. | Synthesis of 5-deoxy-5-oxomilbemycin A4 5-hydrazone derivatives and their activity against Tetranychus urticae | |
| Gold et al. | A simple, high yield method for the nucleophilic substitution of halonitrobenzenes by thiols | |
| CS200171B2 (en) | Process for preparing 1,3-oxazino/5,6-c/rifamycines | |
| US4243596A (en) | (5-Nitro-2-furyl)vinylene-2-trimethylammonium bromide and method of preparing same | |
| JP2020100666A (ja) | 亜硝酸テトラアルキルアンモニウムの製造方法 | |
| SU1015823A3 (ru) | Способ получени таутомеров @ -5-амино-4,5,6,7-тетрагидро-1н-индазола и @ -5-амино-4,5,6,7-тетрагидро-2н-индазола | |
| US4394312A (en) | Process for preparing rifamycin derivatives | |
| SU1447822A1 (ru) | Способ получени оксимов 3-арил-5-метоксикарбонилацетилизоксазолов |